Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.

Kennedy, Alice; Patel, Shyam; Ramanathan, Muthalagu; Gerber, Jonathan; Cerny, Jan

Kennedy, Alice; Patel, Shyam; Ramanathan, Muthalagu; Gerber, Jonathan; Cerny, Jan.

Afiliação

Kennedy A; Tufts Medical Center, Department of Internal Medicine, Boston, MA, USA.
Patel S; University of Massachusetts Chan Medical School, Worcester, MA, USA.
Ramanathan M; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Gerber J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Cerny J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.

Ann Hematol ; 103(3): 1031-1033, 2024 Mar.

Article em En | MEDLINE | ID: mdl-38195923

Assuntos

Leucemia Mieloide Aguda; Inibidores de Proteínas Quinases; Estaurosporina/análogos & derivados; Humanos; Estaurosporina/uso terapêutico; Leucemia Mieloide Aguda/tratamento farmacológico; Leucemia Mieloide Aguda/genética; Tirosina Quinase 3 Semelhante a fms/genética; Mutação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Estaurosporina / Inibidores de Proteínas Quinases Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google